|
|
 Previous Article | Table of Contents | Next Article 
MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells
Gerrard Teoh,
Mitsuyoshi Urashima,
Atsushi Ogata,
Dharminder Chauhan,
James A. DeCaprio,
Steven P. Treon,
Robert L. Schlossman, and
Kenneth C. Anderson
From the Divisions of Hematologic Malignancies and Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston; the Department of Medicine, Harvard Medical School, Boston, MA; the Department of Haematology, Singapore General Hospital, Singapore; and Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.
The murine double minute 2 (MDM2) protein facilitates G1 to S phase transition by activation of E2F-1 and can enhance cell survival by suppressing wild-type p53 (wtp53) function. In this study, we examined MDM2 expression and function in multiple myeloma (MM) cells. MDM2 is strongly and constitutively expressed in MM cell lines (ARH-77, RPMI 8226, and OCI-My5) and in the cells of plasma cell leukemia (PCL) patients, but is not expressed in normal bone marrow mononuclear cells (BM MNCs). Treatment of MM cells with MDM2 antisense, but not sense, nonsense, or scrambled, oligodeoxyribonucleotides (ODNs) decreased DNA synthesis and cell viability; it also induced G1 growth arrest, as evidenced by propidium iodide (PI) staining and induction of retinoblastoma protein (pRB) to E2F-1 binding. Moreover, inhibition of MDM2 using antisense ODNs also triggered MM cell apoptosis as evidenced by acridine orange-ethidium bromide staining. We next studied the association of MDM2 with wtp53 and/or mutant p53 (mtp53), E2F-1, CDK4, and p21. MDM2 constitutively binds to E2F-1 in all MM cells, to both wtp53 and mtp53, and to p21 in tumor cells lacking p53. These data suggest that MDM2 may enhance cell-cycle progression in MM cells both by activating E2F-1 and by downregulating cell-cycle inhibitory proteins (wtp53 and p21). Overexpression of MDM2 may therefore contribute to both growth and survival of MM cells, suggesting the potential utility of treatment strategies targeting MDM2 in MM.
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 1982-1992
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1886 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stuhmer, M. Chatterjee, M. Hildebrandt, P. Herrmann, H. Gollasch, C. Gerecke, S. Theurich, L. Cigliano, R. A. Manz, P. T. Daniel, et al.
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Blood,
November 15, 2005;
106(10):
3609 - 3617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, H. Wang, G. Prasad, M. Li, D. Yu, J. A. Bonner, S. Agrawal, and R. Zhang
Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models
Clin. Cancer Res.,
February 15, 2004;
10(4):
1263 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Catley, E. Weisberg, Y.-T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, et al.
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
Blood,
October 1, 2003;
102(7):
2615 - 2622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Goetz, H. van der Kuip, R. Maya, M. Oren, and W. E. Aulitzky
Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells
Cancer Res.,
October 1, 2001;
61(20):
7635 - 7641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Capoulade, L. M. Mir, K. Carlier, Y. Lecluse, C. Tetaud, Z. Mishal, and J. Wiels
Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides
Blood,
February 15, 2001;
97(4):
1043 - 1049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Flores, B. L. Allen-Hoffmann, D. Lee, and P. F. Lambert
The Human Papillomavirus Type 16 E7 Oncogene Is Required for the Productive Stage of the Viral Life Cycle
J. Virol.,
July 15, 2000;
74(14):
6622 - 6631.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Hofland, B. O. Petersen, J. Falck, K. Helin, P. B. Jensen, and M. Sehested
Differential Cytotoxic Pathways of Topoisomerase I and II Anticancer Agents after Overexpression of the E2F-1/DP-1 Transcription Factor Complex
Clin. Cancer Res.,
April 1, 2000;
6(4):
1488 - 1497.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Teoh, Y.-T. Tai, M. Urashima, S. Shirahama, M. Matsuzaki, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, et al.
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
Blood,
February 1, 2000;
95(3):
1039 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Seavey, M. Holubar, L. J. Saucedo, and M. E. Perry
The E7 Oncoprotein of Human Papillomavirus Type 16 Stabilizes p53 through a Mechanism Independent of p19ARF
J. Virol.,
September 1, 1999;
73(9):
7590 - 7598.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. H.-L. Ng, A. Kan, Y.-F. Chung, I. H.-N. Wong, K.-W. Lo, N. W. R. Wickham, K. I.-K. Lei, and J. C.-K. Lee
Combined Morphological and Interphase Fluorescence in Situ Hybridization Study in Multiple Myeloma of Chinese Patients
Am. J. Pathol.,
January 1, 1999;
154(1):
15 - 22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, H. Gisslinger, M. DeSantis, N. Zojer, M. Fiegl, S. Roka, et al.
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
Blood,
August 1, 1998;
92(3):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, G. Teoh, D. Chauhan, A. Ogata, S. Shirahama, C. Kaihara, M. Matsuzaki, H. Matsushima, M. Akiyama, Y. Yuza, et al.
MDM2 Protein Overexpression Inhibits Apoptosis of TF-1 Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Acute Myeloblastic Leukemia Cells
Blood,
August 1, 1998;
92(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Vincent, M. Jourdan, M.-S. Sy, B. Klein, and N. Mechti
Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein
J. Biol. Chem.,
April 27, 2001;
276(18):
14728 - 14736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
